척수 손상 후 비뇨기 증상을 줄이기 위한 방광내 유산균
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Urinary tract infection (UTI) is the most common outpatient infection world-wide, and for people with spinal cord injury (SCI) and neurogenic bladder (NB), it is the most common infection, secondary condition, cause for emergency room visits, and infectious cause of hospitalization. Despite its prevalence, attempts to ameliorate UTI among people with SCI are stymied by long-standing diagnostic challenges which arise from evidence gaps around "gold standard" diagnostic tests (urinalysis and urine culture) that have lower sensitivity and specificity for UTI in this population. A high prevalence of chronic inflammation leading to persistence of white blood cells (WBC) in the urine confounds the utility of WBC count, pyuria, and leukocyte esterase as biomarkers for UTI; nitrites in urine indicate the presence of only specific (but not all) organisms, many of which are present to a greater extent in the urine of people with SCI; and people with SCI have a high prevalence of asymptomatic bacteriuria. These physiologic changes render the gold standard diagnostic tests less useful for identifying UTI in persons with SCI.
SPECIFIC AIM 1
2 urine samples (sampling at least 2 weeks apart) for urinalysis, urine culture, uNGAL, and NGS (16S rRNA and shotgun) under the same conditions. In addition to completing the USQNB-IC prior to urine collection, participants will complete the USQNB-IC 3 days after urine collection
SPECIFIC AIM 2 Intravesical LGG dose (group: high or low) will be obtained, USQNB-IC, urine collection for urinalysis, culture, NGAL and next generation sequencing as described above. And patient satisfaction questions.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- MedStar National Rehabilitation Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- SCI at least 1-year duration;
- Neurogenic bladder;
- Utilizing intermittent catheterization for bladder management;
- Women must be premenopausal and not currently menstruating;
- Community dwelling
Exclusion Criteria:
- Use of prophylactic antibiotics;
- Instillation of intravesical antimicrobials to prevent UTI;
- Psychologic or psychiatric conditions influencing the ability to follow instructions;
- Use of oral or IV antibiotics within the past 2 weeks;
- Sexual activity within the previous 72 hours;
- Participation in another study with which results could be confounded.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Low Dosage Group
For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion. |
For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules
다른 이름들:
|
|
실험적: High Dosage Group
For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion. |
For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants With Successful Reduction of Urinary Symptoms
기간: Participants (low and high group) fill out the USQNB-IC at the onset of their symptoms, and 48 hours after the last dose. Definition of "success" is 20% reduction in number of endorsed symptoms between the first and final USQNB-IC.
|
20% reduction in urinary symptoms within 48 hours of completion of intervention |
Participants (low and high group) fill out the USQNB-IC at the onset of their symptoms, and 48 hours after the last dose. Definition of "success" is 20% reduction in number of endorsed symptoms between the first and final USQNB-IC.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Leukocyte Esterase
기간: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 36 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
urinary leukocyte esterase level (ordinal count levels) |
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 36 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
|
Change in Cultivable Bacteria Pre and Post LGG Instillations
기간: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
Standard urine culture (SUC) results based on quantity (colony forming units) and identified organism. (number of organisms cultivated/identified; yes/no if any were cultivated at or greater than 10^5) |
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
|
Change in Urine Nitrite Pre and Post LGG Instillations
기간: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
Standard urine analysis. Urine derived nitrites (positive or negative) |
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
|
Change in Urine White Blood Cell Count Pre and Post LGG Instillations
기간: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
urine derived white blood cells per high powered field (ordinal count levels) |
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
|
Change in uNGAL Pre and Post LGG Instillations
기간: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
urinary neutrophil gelatinase-associated lipocalin in µg/L (continuous) |
Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Suzanne Groah, MD, MSPH, MedStar National Rehabilitation Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- STUDY00001124
- CDMRP-eBRAP Log Number (기타 식별자: CDMRP-SC180210)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .